Cancer is a major problem threatening human life nowadays. All kinds of cancers afflict patients and sometimes they are unable to be detected at the early stage.
In the past, we had to BIOPSY the tumor tissue with an endoscope and a needle, and then undergo a surgery to do laboratory tests to confirm the genetic information of the cancer cells. At present, EXCEDO-T analyzes the expression of cancer-specific microRNA in the blood to assess the risk of occurrence of cancers (less than 5 mm) at ultra-early stage that cannot be detected by imaging (PET, CT, MRI, endoscopy, etc.). EXCEDO-T can detect cancers at an extremely early stage and enable groundbreaking medical technology to analyze cancer gene mutations, which makes different from traditional tests. Tumor markers and other traditional tests respond to the pre-stage and imaging tests are difficult to detect small-sized and early stage cancers. The possibility of early detection of cancer is significantly improved.
In addition, the company has cooperated with domestic and foreign universities, research facilities, medical institutions and other colleges in joint research and development, and through such a network, EXCEDO-T has still further enhanced its accuracy and speed.
